Table 1. Shared and divergent... | American Society of Hematology

Table 1.

Shared and divergent characteristics of CLL and MCL

Characteristic	CLL	MCL
Incidence*^,4	5.1	0.8
Hereditary susceptibility†^,⁸	2.4- to 8.5-fold risk	2-fold risk
Demographics^1,4-7	Elderly patients
	Males > Females
	More common in Caucasians
	Less frequent in Asians
Initial oncogenic events¹	del(13q), del(11q), tri(12), other (?)	t(11;14), SOX11
Phenotype¹
SIg	Dim IgM, IgD	Strong IgM, IgD
CD5	+	+
CD20	Weak	Strong
CD23	+	−
CD200	+	−
Cytogenetic alterations¹	del(13q); del(11q); del(17p)
		t(11;14); del(9p); genomic instability
Somatic mutations^66,67,116	DNA damage response pathway (ATM, TP53)
	NF-κB pathway
	NOTCH1	NOTCH1/NOTCH2
	SF3B1 and splicing machinery	Chromatin modifiers
	MYD88	CDKN2A del
MicroRNA dysregulation¹⁶⁷	miR-16-1, miR-29 a/b/c, miR-34a, miR-150, miR-155, miR-181
	miR-15a, miR-21, miR-223, miR-650	miR-17-92, miR-20b, miR-142-3p

Characteristic	CLL	MCL
Incidence*^,4	5.1	0.8
Hereditary susceptibility†^,⁸	2.4- to 8.5-fold risk	2-fold risk
Demographics^1,4-7	Elderly patients
	Males > Females
	More common in Caucasians
	Less frequent in Asians
Initial oncogenic events¹	del(13q), del(11q), tri(12), other (?)	t(11;14), SOX11
Phenotype¹
SIg	Dim IgM, IgD	Strong IgM, IgD
CD5	+	+
CD20	Weak	Strong
CD23	+	−
CD200	+	−
Cytogenetic alterations¹	del(13q); del(11q); del(17p)
		t(11;14); del(9p); genomic instability
Somatic mutations^66,67,116	DNA damage response pathway (ATM, TP53)
	NF-κB pathway
	NOTCH1	NOTCH1/NOTCH2
	SF3B1 and splicing machinery	Chromatin modifiers
	MYD88	CDKN2A del
MicroRNA dysregulation¹⁶⁷	miR-16-1, miR-29 a/b/c, miR-34a, miR-150, miR-155, miR-181
	miR-15a, miR-21, miR-223, miR-650	miR-17-92, miR-20b, miR-142-3p

SIg, surface immunoglobulin.

Rates are per 100 000 and age adjusted to the US standard population;

Risk of first-degree relatives of CLL and MCL of developing CLL or non-Hodgkin lymphomas, respectively.